Gary W Falk

List of Publications by Year
in descending order

249 papers	17,937 citations	19608 61 h-index	14156 128 g-index
275 all docs	275 docs citations	275 times ranked	7726 citing authors

#	Article	IF	Citations
1	Eosinophilic esophagitis: Updated consensus recommendations for children and adults. Journal of Allergy and Clinical Immunology, 2011, 128, 3-20.e6.	1.5	1,839
2	Radiofrequency Ablation in Barrett's Esophagus with Dysplasia. New England Journal of Medicine, 2009, 360, 2277-2288.	13.9	1,348
3	ACG Clinical Guideline: Diagnosis and Management of Barrettâ€™s Esophagus. American Journal of Gastroenterology, 2016, 111, 30-50.	0.2	1,275
4	Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference. Gastroenterology, 2018, 155, 1022-1033.e10.	0.6	712
5	A critical review of the diagnosis and management of Barrettâ€™s esophagus: the ACA Chicago Workshop1 1Members of the workshop composed a group of international experts in BE from gastroenterology, surgery, pathology, molecular biology, outcomes, and epidemiology. Conference chairman: Prateek Sharma; conference moderator: Kenneth McQuaid; group leaders: John Dent, M. Brian Fennerty, Richard Sampliner, Stuart Spechler; participants: Alan Cameron, Douglas Corley, Gary Falk, John Goldblum, John Hunter, Janusz Ja. Gastroenterology, 2004, 127, 310-330.	0.6	579
6	Durability of Radiofrequency Ablation in Barrett's Esophagus With Dysplasia. Gastroenterology, 2011, 141, 460-468.	0.6	432
7	Dysplasia and Cancer in a Large Multicenter Cohort of Patients With Barrettâ€™s Esophagus. Clinical Gastroenterology and Hepatology, 2006, 4, 566-572.	2.4	388
8	The seroprevalence of cagA-positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease. Gastroenterology, 1998, 115, 50-57.	0.6	369
9	Consensus Statements for Management of Barrett's Dysplasia and Early-Stage Esophageal Adenocarcinoma, Based on a Delphi Process. Gastroenterology, 2012, 143, 336-346.	0.6	365
10	Thymic stromal lymphopoietinâ€“elicited basophil responses promote eosinophilic esophagitis. Nature Medicine, 2013, 19, 1005-1013.	15.2	351
11	Barrett's esophagus. Gastroenterology, 2002, 122, 1569-1591.	0.6	345
12	Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis. Gastroenterology, 2020, 158, 111-122.e10.	0.6	300
13	Jumbo biopsy forceps protocol still misses unsuspected cancer in Barrett's esophagus with high-grade dysplasia. Gastrointestinal Endoscopy, 1999, 49, 170-176.	0.5	292
14	Inflammation and intestinal metaplasia of the gastric cardia: The role of gastroesophageal reflux and H. pylori infection. Gastroenterology, 1998, 114, 633-639.	0.6	261
15	Risk Factors for Progression of Low-Grade Dysplasia in Patients With Barrett's Esophagus. Gastroenterology, 2011, 141, 1179-1186.e1.	0.6	238
16	Recurrence of Esophageal Intestinal Metaplasia After Endoscopic Mucosal Resection and Radiofrequency Ablation of Barrett's Esophagus: Results From a US Multicenter Consortium. Gastroenterology, 2013, 145, 79-86.e1.	0.6	222
17	The gastric cardia: fact or fiction?. American Journal of Gastroenterology, 2000, 95, 921-924.	0.2	221
18	The incidence of adenocarcinoma and dysplasia in Barrett's esophagus Report on the cleveland clinic barrett's esophagus registry. American Journal of Gastroenterology, 1999, 94, 2037-2042.	0.2	220

#	Article	IF	Citations
19	Patients With Nondysplastic Barrett's Esophagus Have Low Risks for Developing Dysplasia or Esophageal Adenocarcinoma. Clinical Gastroenterology and Hepatology, 2011, 9, 220-227.e1.	2.4	211
20	In vivo endomicroscopy improves detection of Barrett's esophagusâ€“related neoplasia: a multicenter international randomized controlled trial (with video). Gastrointestinal Endoscopy, 2014, 79, 211-221.	0.5	183
21	The Incidence of Adenocarcinoma and Dysplasia in Barrett's Esophagus: Report on The Cleveland Clinic Barrett's Esophagus Registry. American Journal of Gastroenterology, 1999, 94, 2037-2042.	0.2	167
22	Caga-positive strains of Helicobacter pylori may protect against Barrett's esophagus. American Journal of Gastroenterology, 2000, 95, 2206-2211.	0.2	166
23	Budesonide Oral Suspension Improves Symptomatic, Endoscopic, and Histologic Parameters Compared WithÂPlaceboÂin Patients With Eosinophilic Esophagitis. Gastroenterology, 2017, 152, 776-786.e5.	0.6	166
24	Diagnosis and Management of Barrett's Esophagus: An Updated ACG Guideline. American Journal of Gastroenterology, 2022, 117, 559-587.	0.2	159
25	An open-label, prospective trial of cryospray ablation for Barrett's esophagus high-grade dysplasia and early esophageal cancer in high-risk patients. Gastrointestinal Endoscopy, 2009, 70, 635-644.	0.5	156
26	Superficial adenocarcinoma of the esophagus. Journal of Thoracic and Cardiovascular Surgery, 2001, 122, 1077-1090.	0.4	147
27	The American Society for Gastrointestinal Endoscopy PIVI (Preservation and Incorporation of) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 2012, 76, 252-254.	0.5	140
28	Practice patterns for surveillance of Barrett's esophagus in the United States. Gastrointestinal Endoscopy, 2000, 52, 197-203.	0.5	138
29	Eosinophilic oesophagitis endotype classification by molecular, clinical, and histopathological analyses: a cross-sectional study. The Lancet Gastroenterology and Hepatology, 2018, 3, 477-488.	3.7	135
30	Development of Subsquamous High-Grade Dysplasia and Adenocarcinoma After Successful Radiofrequency Ablation of Barrett's Esophagus. Gastroenterology, 2012, 143, 564-566.e1.	0.6	128
31	p53 expression in low grade dysplasia in Barrett's esophagus: correlation with interobserver agreement and disease progression. American Journal of Gastroenterology, 2002, 97, 2508-2513.	0.2	124
32	Association Between Length of Barrett's Esophagus and Risk of High-grade Dysplasia or Adenocarcinoma in Patients Without Dysplasia. Clinical Gastroenterology and Hepatology, 2013, 11, 1430-1436.	2.4	117
33	BOB CAT: a Large-Scale Review and Delphi Consensus for Management of Barrettâ€™s Esophagus With No Dysplasia, Indefinite for, or Low-Grade Dysplasia. American Journal of Gastroenterology, 2015, 110, 662-682.	0.2	116
34	Cytokeratin immunoreactivity patterns in the diagnosis of short-segment Barrett's esophagus. Gastroenterology, 2000, 119, 683-690.	0.6	114
35	T-Helper 2 Cytokines, Transforming Growth Factor Î²1, and Eosinophil Products Induce Fibrogenesis and Alter Muscle Motility in Patients With Eosinophilic Esophagitis. Gastroenterology, 2014, 146, 1266-1277.e9.	0.6	114
36	Development and Validation of a Model to Determine Risk of Progression of Barrettâ€™s Esophagus to Neoplasia. Gastroenterology, 2018, 154, 1282-1289.e2.	0.6	107

#	Article	IF	Citations
37	Familiality in Barrett's Esophagus, Adenocarcinoma of the Esophagus, and Adenocarcinoma of the Gastroesophageal Junction. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 1668-1673.	1.1	104
38	Endosonography in the evaluation of patients with Barrett's esophagus and high-grade dysplasia. Gastrointestinal Endoscopy, 1994, 40, 207-212.	0.5	99
39	Risk factors for dysplasia in patients with Barrett's esophagus (BE): results from a multicenter consortium. Digestive Diseases and Sciences, 2003, 48, 1537-1541.	1.1	99
40	Inflammatory mediators in gastroesophageal reflux disease: impact on esophageal motility, fibrosis, and carcinogenesis. American Journal of Physiology - Renal Physiology, 2010, 298, G571-G581.	1.6	99
41	Late Recurrence of Barrettâ€™s Esophagus After Complete Eradication of Intestinal Metaplasia is Rare: Final Report From Ablation in Intestinal Metaplasia Containing Dysplasia Trial. Gastroenterology, 2017, 153, 681-688.e2.	0.6	99
42	Helicobacter pylori and gastroesophageal reflux disease: the bug may not be all bad. American Journal of Gastroenterology, 1998, 93, 1800-1802.	0.2	98
43	Eosinophilic Esophagitis. JAMA - Journal of the American Medical Association, 2021, 326, 1310.	3.8	98
44	The Seattle Protocol Does Not More Reliably Predict the Detection of Cancer at the Time of Esophagectomy Than a Less Intensive Surveillance Protocol. Clinical Gastroenterology and Hepatology, 2009, 7, 653-658.	2.4	94
45	Risk Factors for Esophageal Cancer Development. Surgical Oncology Clinics of North America, 2009, 18, 469-485.	0.6	92
46	Increasing Rates of Diagnosis, Substantial Co-Occurrence, and Variable Treatment Patterns of Eosinophilic Gastritis, Gastroenteritis, and Colitis Based on 10-Year Data Across a Multicenter Consortium. American Journal of Gastroenterology, 2019, 114, 984-994.	0.2	92
47	Health-Related Quality of Life and Costs Associated With Eosinophilic Esophagitis: A Systematic Review. Clinical Gastroenterology and Hepatology, 2018, 16, 495-503.e8.	2.4	90
48	BMP-driven NRF2 activation in esophageal basal cell differentiation and eosinophilic esophagitis. Journal of Clinical Investigation, 2015, 125, 1557-1568.	3.9	90
49	A coxib a day won't keep the doctor away. Lancet, The, 2004, 364, 639-640.	6.3	88
50	Gastroesophageal reflux symptoms in patients with adenocarcinoma of the esophagus or cardia. Cancer, 2006, 107, 2160-2166.	2.0	87
51	Increased detection of Barrettâ€™s esophagusâ€“associated neoplasia using wide-area trans-epithelial sampling: aÂmulticenter, prospective, randomized trial. Gastrointestinal Endoscopy, 2018, 87, 348-355.	0.5	87
52	Helicobacter pylori infection, not gastroesophageal reflux, is the major cause of inflammation and intestinal metaplasia of gastric cardiac mucosa. American Journal of Gastroenterology, 2002, 97, 302-311.	0.2	83
53	Persistence of Nondysplastic Barrett's Esophagus Identifies Patients at Lower Risk for Esophageal Adenocarcinoma: Results From a Large Multicenter Cohort. Gastroenterology, 2013, 145, 548-553.e1.	0.6	81
54	Quality Indicators for the Management of Barrettâ€™s Esophagus, Dysplasia, and Esophageal Adenocarcinoma: International Consensus Recommendations from the American Gastroenterological Association Symposium. Gastroenterology, 2015, 149, 1599-1606.	0.6	81

#	Article	IF	Citations
55	Radiofrequency Ablation Is Associated With Decreased Neoplastic Progression in Patients With Barrett's Esophagus and Confirmed Low-Grade Dysplasia. Gastroenterology, 2015, 149, 567-576.e3.	0.6	77
56	The Role of Allergy Evaluation in Adults With Eosinophilic Esophagitis. Journal of Clinical Gastroenterology, 2010, 44, 22-27.	1.1	74
57	The Esophageal Organoid System Reveals Functional Interplay Between Notch and Cytokines in Reactive EpithelialÂChanges. Cellular and Molecular Gastroenterology and Hepatology, 2018, 5, 333-352.	2.3	72
58	Association of insulin and insulin-like growth factors with Barrett's oesophagus. Gut, 2012, 61, 665-672.	6.1	71
59	Observer variation and reproducibility of endoscopic ultrasonography. Gastrointestinal Endoscopy, 1995, 41, 115-120.	0.5	69
60	Barrett's Esophagus at a Tertiary Care Center: Association of Age on Incidence and Prevalence of Dysplasia and Adenocarcinoma. American Journal of Gastroenterology, 2006, 101, 2187-2193.	0.2	66
61	Gastric and Esophageal pH in Patients With Barrett's Esophagus Treated With Three Esomeprazole Dosages: A Randomized, Double-Blind, Crossover Trial. American Journal of Gastroenterology, 2006, 101, 1964-1971.	0.2	66
62	A Combination of Esomeprazole and Aspirin Reduces Tissue Concentrations of Prostaglandin E2 in Patients With Barrett's Esophagus. Gastroenterology, 2012, 143, 917-926.e1.	0.6	58
63	Long-term outcomes of patients with Barrett's esophagus and high-grade dysplasia or early cancer treated with endoluminal therapies with intention to complete eradication. Gastrointestinal Endoscopy, 2013, 77, 190-199.	0.5	58
64	Budesonide Oral Suspension Improves Outcomes in Patients With Eosinophilic Esophagitis: Results From a Phase 3 Trial. Clinical Gastroenterology and Hepatology, 2022, 20, 525-534.e10.	2.4	57
65	International Consensus Recommendations for Eosinophilic Gastrointestinal Disease Nomenclature. Clinical Gastroenterology and Hepatology, 2022, 20, 2474-2484.e3.	2.4	57
66	Role ofHelicobacter pylori cagA+ strains and specific host immune responses on the development of premalignant and malignant lesions in the gastric cardia. , 1999, 82, 520-524.		55
67	Low Risk of High-Grade Dysplasia or Esophageal Adenocarcinoma Among Patients With Barrett's Esophagus Less Than 1 cm (Irregular Z Line) Within 5 Years of Index Endoscopy. Gastroenterology, 2017, 152, 987-992.	0.6	54
68	Chromosomal gains and genomic loss of p53 and p16 genes in Barrett's esophagus detected by fluorescence in situ hybridization of cytology specimens. Modern Pathology, 2004, 17, 588-596.	2.9	53
69	AGA Institute Technical Review on the Use of Endoscopic Therapy for Gastroesophageal Reflux Disease. Gastroenterology, 2006, 131, 1315-1336.	0.6	53
70	Lower Annual Rate of Progression of Short-Segment vs Long-Segment Barrettâ€™s Esophagus to Esophageal Adenocarcinoma. Clinical Gastroenterology and Hepatology, 2019, 17, 864-868.	2.4	51
71	Molecular, endoscopic, histologic, and circulating biomarker-based diagnosis of eosinophilic gastritis: Multi-site study. Journal of Allergy and Clinical Immunology, 2020, 145, 255-269.	1.5	51
72	Esophageal manometry: Assessment of interpreter consistency. Clinical Gastroenterology and Hepatology, 2005, 3, 218-224.	2.4	50

#	Article	IF	Citations
73	Development of quality indicators for endoscopic eradication therapies in Barrettâ€™s esophagus: the TREAT-BE (Treatment with Resection and Endoscopic Ablation Techniques for Barrettâ€™s Esophagus) Consortium. Gastrointestinal Endoscopy, 2017, 86, 1-17.e3.	0.5	50
74	Notch Signaling Mediates Differentiation in Barrettâ€™s Esophagus and Promotes Progression to Adenocarcinoma. Gastroenterology, 2020, 159, 575-590.	0.6	49
75	Is FDG-PET indicated for superficial esophageal cancer?â˜†. European Journal of Cardio-thoracic Surgery, 2007, 31, 791-796.	0.6	48
76	p53 Immunoreactivity in Barrett's metaplasia, dysplasia, and carcinoma. Journal of Thoracic and Cardiovascular Surgery, 1994, 108, 1132-1137.	0.4	47
77	The American Society for Gastrointestinal Endoscopy PIVI (Preservation and Incorporation of) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T 81, 1087-1100.e1.	0.5	47
78	A Tissue Systems Pathology Assay for High-Risk Barrett's Esophagus. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 958-968.	1.1	45
79	Alignment of parent- and child-reported outcomes and histology in eosinophilic esophagitis across multiple CEGIR sites. Journal of Allergy and Clinical Immunology, 2018, 142, 130-138.e1.	1.5	45
80	Generation and Characterization of Patientâ€Derived Head and Neck, Oral, and Esophageal Cancer Organoids. Current Protocols in Stem Cell Biology, 2020, 53, e109.	3.0	45
81	Assessment of Familiality, Obesity and Other Risk Factors for Early Age of Cancer Diagnosis in Adenocarcinomas of the Esophagus and Gastroesophageal Junction. American Journal of Gastroenterology, 2009, 104, 1913-1921.	0.2	44
82	Positive correlation between endoscopist radiofrequency ablation volume and response rates in Barrett's esophagus. Gastrointestinal Endoscopy, 2014, 80, 71-77.	0.5	44
83	Association Between Endoscopic and Histologic Findings in a Multicenter Retrospective Cohort of Patients with Non-esophageal Eosinophilic Gastrointestinal Disorders. Digestive Diseases and Sciences, 2020, 65, 2024-2035.	1.1	44
84	Autophagy mediates epithelial cytoprotection in eosinophilic oesophagitis. Gut, 2017, 66, 1197-1207.	6.1	43
85	Metformin Does Not Reduce Markers of Cell Proliferation in Esophageal Tissues of Patients With Barrettâ€™s Esophagus. Clinical Gastroenterology and Hepatology, 2015, 13, 665-672.e4.	2.4	42
86	Clinical Guidelines Update on the Diagnosis and Management of Barrettâ€™s Esophagus. Digestive Diseases and Sciences, 2018, 63, 2122-2128.	1.1	42
87	Persistent Basal Cell Hyperplasia Is Associated With Clinical and Endoscopic Findings in Patients With Histologically Inactive Eosinophilic Esophagitis. Clinical Gastroenterology and Hepatology, 2020, 18, 1475-1482.e1.	2.4	42
88	Fibrostenotic eosinophilic esophagitis might reflect epithelial lysyl oxidase induction by fibroblast-derived TNF-Î±. Journal of Allergy and Clinical Immunology, 2019, 144, 171-182.	1.5	41
89	Autofluorescence Endoscopy. Gastrointestinal Endoscopy Clinics of North America, 2009, 19, 209-220.	0.6	40
90	Location, location, location: does early cancer in Barrettâ€™s esophagus have a preference?. Gastrointestinal Endoscopy, 2013, 78, 462-467.	0.5	40

#	Article	IF	Citations
91	Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS). Journal of Allergy and Clinical Immunology, 2022, 149, 659-670.	1.5	40
92	Acid suppression therapy may not alter malignant progression in Barrett's metaplasia showing p53 protein accumulation. American Journal of Gastroenterology, 2002, 97, 1340-1345.	0.2	39
93	A Segregation Analysis of Barrett's Esophagus and Associated Adenocarcinomas. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 666-674.	1.1	39
94	Pathogenesis of Gastroesophageal Reflux and Barrett Esophagus. Mayo Clinic Proceedings, 2001, 76, 226-234.	1.4	38
95	Barrettâ€™s Esophagus in Women: Demographic Features and Progression to High-Grade Dysplasia and Cancer. Clinical Gastroenterology and Hepatology, 2005, 3, 1089-1094.	2.4	38
96	Development of Quality Indicators for Endoscopic Eradication Therapies in Barrettâ€™s Esophagus: The TREAT-BE (Treatment With Resection and Endoscopic Ablation Techniques for Barrettâ€™s Esophagus) Consortium. American Journal of Gastroenterology, 2017, 112, 1032-1048.	0.2	38
97	Esophageal epithelial cells acquire functional characteristics of activated myofibroblasts after undergoing an epithelial to mesenchymal transition. Experimental Cell Research, 2015, 330, 102-110.	1.2	37
98	Esophageal type 2 cytokine expression heterogeneity in eosinophilic esophagitis in a multisite cohort. Journal of Allergy and Clinical Immunology, 2020, 145, 1629-1640.e4.	1.5	37
99	A Tissue Systems Pathology Test Detects Abnormalities Associated with Prevalent High-Grade Dysplasia and Esophageal Cancer in Barrett's Esophagus. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 240-248.	1.1	36
100	Comparative risk of recurrence of dysplasia and carcinoma after endoluminal eradication therapy of high-grade dysplasia versus intramucosal carcinoma in Barrettâ€™s esophagus. Gastrointestinal Endoscopy, 2015, 81, 1158-1166.e4.	0.5	34
101	Should wheat, barley, rye, and/or gluten be avoided in a 6-food elimination diet?. Journal of Allergy and Clinical Immunology, 2016, 137, 1011-1014.	1.5	34
102	Esophageal cancer: The latest on chemoprevention and state of the art therapies. Pharmacological Research, 2016, 113, 236-244.	3.1	33
103	Cryotherapy and Radiofrequency Ablation for Eradication of Barrettâ€™s Esophagus with Dysplasia or Intramucosal Cancer. Digestive Diseases and Sciences, 2018, 63, 1311-1319.	1.1	33
104	Outcomes of patients with submucosal (T1b) esophageal adenocarcinoma: a multicenter cohort study. Gastrointestinal Endoscopy, 2020, 92, 31-39.e1.	0.5	33
105	A Clinical Severity Index for Eosinophilic Esophagitis: Development, Consensus, and Future Directions. Gastroenterology, 2022, 163, 59-76.	0.6	33
106	Endoscopic surveillance of Barrett's esophagus: risk stratification and cancer risk. Gastrointestinal Endoscopy, 1999, 49, S29-S34.	0.5	31
107	Creating a multi-center rare disease consortium â€“ the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). Translational Science of Rare Diseases, 2017, 2, 141-155.	1.6	30
108	Fluorescence in situ hybridization of cytologic specimens from Barrett's esophagus: a pilot feasibility study. Gastrointestinal Endoscopy, 2004, 60, 280-284.	0.5	29

#	Article	IF	Citations
109	Eosinophilic Esophagitisâ€Associated Chemical and Mechanical Microenvironment Shapes Esophageal Fibroblast Behavior. Journal of Pediatric Gastroenterology and Nutrition, 2016, 63, 200-209.	0.9	29
110	Randomised clinical trial: the safety and tolerability of fluticasone propionate orally disintegrating tablets versus placebo for eosinophilic oesophagitis. Alimentary Pharmacology and Therapeutics, 2020, 51, 750-759.	1.9	29
111	Modeling inflammation and oxidative stress in gastrointestinal disease development using novel organotypic culture systems. Stem Cell Research and Therapy, 2013, 4, S5.	2.4	28
112	Determination of Biopsy Yield That Optimally Detects Eosinophilic Gastritis and/or Duodenitis in a Randomized Trial of Lirentelimab. Clinical Gastroenterology and Hepatology, 2022, 20, 535-545.e15.	2.4	28
113	Virtual Dysphagia Evaluation: Practical Guidelines for Dysphagia Management in the Context of the COVID-19 Pandemic. Otolaryngology - Head and Neck Surgery, 2020, 163, 455-458.	1.1	28
114	Variation in Age at Cancer Diagnosis in Familial versus Nonfamilial Barrett's Esophagus. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 376-383.	1.1	26
115	213 A Randomized, Multicenter, Sham-Controlled Trial of Radiofrequency Ablation (RFA) for Subjects with Barrett's Esophagus (Be) Containing Dysplasia: Interim Results of the Aim Dysplasia Trial. Gastroenterology, 2008, 134, A-37.	0.6	25
116	Consortium of Eosinophilic Gastrointestinal Disease Researchers: Advancing the Field of Eosinophilic GI Disorders Through Collaboration. Gastroenterology, 2019, 156, 838-842.	0.6	25
117	Management of Nondysplastic Barrett's Esophagus: Where Are We Now?. American Journal of Gastroenterology, 2009, 104, 805-808.	0.2	24
118	Barrett's esophagus: prevalenceâ€“incidence and etiologyâ€“origins. Annals of the New York Academy of Sciences, 2011, 1232, 1-17.	1.8	24
119	Associations of Serum Adiponectin and Leptin With Barrettâ€™s Esophagus. Clinical Gastroenterology and Hepatology, 2015, 13, 2265-2272.	2.4	23
120	Effect of pneumatic dilation on gastroesophageal reflux in achalasia. Digestive Diseases and Sciences, 1997, 42, 998-1002.	1.1	22
121	Clinical outcomes in patients with a diagnosis of â€œindefinite for dysplasiaâ€•in Barrettâ€™s esophagus: a multicenter cohort study. Endoscopy, 2015, 47, 669-674.	1.0	22
122	Eosinophilic esophagitis: An increasingly recognized cause of dysphagia, food impaction, and refractory heartburn. Cleveland Clinic Journal of Medicine, 2008, 75, 623-633.	0.6	22
123	Loss of Endothelial TSPAN12 Promotes Fibrostenotic Eosinophilic Esophagitis via Endothelial Cellâ€“Fibroblast Crosstalk. Gastroenterology, 2022, 162, 439-453.	0.6	22
124	Long-Term Treatment of Eosinophilic Esophagitis With Budesonide Oral Suspension. Clinical Gastroenterology and Hepatology, 2022, 20, 1488-1498.e11.	2.4	21
125	Wide-area transepithelial sampling for dysplasia detection in Barrettâ€™s esophagus: a systematic review and meta-analysis. Gastrointestinal Endoscopy, 2022, 95, 51-59.e7.	0.5	21
126	Evaluating Eosinophilic Colitis as a Unique Disease Using Colonic Molecular Profiles: A Multi-Site Study. Gastroenterology, 2022, 162, 1635-1649.	0.6	21

#	Article	IF	Citations
127	Extent of Low-Grade Dysplasia in Barrett's Esophagus: Is It Useful for Risk Stratification?. American Journal of Gastroenterology, 2007, 102, 494-496.	0.2	20
128	Predictors of Progression to High-Grade Dysplasia or Adenocarcinoma in Barrettâ€™s Esophagus. Gastroenterology Clinics of North America, 2015, 44, 299-315.	1.0	20
129	Autophagy levels are elevated in barrett's esophagus and promote cell survival from acid and oxidative stress. Molecular Carcinogenesis, 2016, 55, 1526-1541.	1.3	20
130	Achalasia Patients Are at Nutritional Risk Regardless of Presenting Weight Category. Digestive Diseases and Sciences, 2018, 63, 1243-1249.	1.1	20
131	Increasing prevalence of high-grade dysplasia and adenocarcinoma on index endoscopy in Barrettâ€™s esophagus over the past 2 decades: data from a multicenter U.S. consortium. Gastrointestinal Endoscopy, 2019, 89, 257-263.e3.	0.5	20
132	Patient-derived organoids as a platform for modeling a patientâ€™s response to chemoradiotherapy in esophageal cancer. Scientific Reports, 2021, 11, 21304.	1.6	20
133	Effect of ozone and nitrogen dioxide on the agglutination of rat alveolar macrophages by concanavalin A. Life Sciences, 1977, 21, 1637-1644.	2.0	19
134	Cytology in Barrett's esophagus. Gastrointestinal Endoscopy Clinics of North America, 2003, 13, 335-348.	0.6	19
135	Substantial Variability in Biopsy Practice Patterns Among Gastroenterologists for Suspected Eosinophilic Gastrointestinal Disorders. Clinical Gastroenterology and Hepatology, 2016, 14, 1842-1844.	2.4	19
136	High Patient Disease Burden in a Crossâ€sectional, Multicenter Contact Registry Study of Eosinophilic Gastrointestinal Diseases. Journal of Pediatric Gastroenterology and Nutrition, 2020, 71, 524-529.	0.9	19
137	Modeling Epithelial Homeostasis and Reactive Epithelial Changes in Human and Murine Threeâ€Dimensional Esophageal Organoids. Current Protocols in Stem Cell Biology, 2020, 52, e106.	3.0	19
138	Characterization of Prevalent, Post-Endoscopy, and Incident Esophageal Cancer in the United States: A Large Retrospective Cohort Study. Clinical Gastroenterology and Hepatology, 2022, 20, 1739-1747.	2.4	19
139	Barrettâ€™s Esophagus. Gastrointestinal Endoscopy Clinics of North America, 1994, 4, 773-789.	0.6	18
140	AGA Institute Medical Position Statement on the Use of Endoscopic Therapy for Gastroesophageal Reflux Disease. Gastroenterology, 2006, 131, 1313-1314.	0.6	18
141	Low Yield of Cross-Sectional Imaging in Patients With Esophagogastric Junction Outflow Obstruction. Clinical Gastroenterology and Hepatology, 2020, 18, 1643-1644.	2.4	18
142	An Analysis of the GIQuIC Nationwide Quality Registry Reveals Unnecessary Surveillance Endoscopies in Patients With Normal and Irregular Z-Lines. American Journal of Gastroenterology, 2020, 115, 1869-1878.	0.2	18
143	Reliability and responsiveness of endoscopic disease activity assessment in eosinophilic esophagitis. Gastrointestinal Endoscopy, 2022, 95, 1126-1137.e2.	0.5	18
144	Poor discriminatory function for endoscopic skills on a computer-based simulator. Gastrointestinal Endoscopy, 2012, 76, 993-1002.	0.5	17

#	Article	IF	Citations
145	Role of barium esophagography in evaluating dysphagia. Cleveland Clinic Journal of Medicine, 2009, 76, 105-111.	0.6	17
146	Prospective Endoscopic Activity Assessment for Eosinophilic Gastritis in a Multisite Cohort. American Journal of Gastroenterology, 2022, 117, 413-423.	0.2	17
147	Clinical Presentation of Eosinophilic Esophagitis in Adults. Gastroenterology Clinics of North America, 2014, 43, 231-242.	1.0	16
148	Findings of Esophagography for 25 Patients After Peroral Endoscopic Myotomy for Achalasia. American Journal of Roentgenology, 2016, 207, 1185-1193.	1.0	16
149	Variation in Endoscopic Activity Assessment and Endoscopy Score Validation in Adults With Eosinophilic Esophagitis. Clinical Gastroenterology and Hepatology, 2019, 17, 1477-1488.e10.	2.4	16
150	Fluticasone Propionate Orally Disintegrating Tablet (APT-1011) for Eosinophilic Esophagitis: Randomized Controlled Trial. Clinical Gastroenterology and Hepatology, 2022, 20, 2485-2494.e15.	2.4	16
151	Modeling human gastrointestinal inflammatory diseases using microphysiological culture systems. Experimental Biology and Medicine, 2014, 239, 1108-1123.	1.1	15
152	Consortium approach to identifying genes for Barrettâ€™s esophagus and esophageal adenocarcinoma. Translational Research, 2007, 150, 3-17.	2.2	14
153	Subsquamous Intestinal Metaplasia: Implications for Endoscopic Management of Barrett's Esophagus. Clinical Gastroenterology and Hepatology, 2012, 10, 220-224.	2.4	14
154	Evaluation of Mutational Testing of Preneoplastic Barrett's Mucosa by Next-Generation Sequencing of Formalin-Fixed, Paraffin-Embedded Endoscopic SamplesÂfor Detection of Concurrent Dysplasia andÂAdenocarcinoma in Barrett's Esophagus. Journal of Molecular Diagnostics, 2015, 17, 412-419.	1.2	14
155	Mast cellâ€pain connection in eosinophilic esophagitis. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1895-1899.	2.7	14
156	Unresolved Issues in Barrettâ€™s Esophagus in the New Millennium. Digestive Diseases, 2000, 18, 27-42.	0.8	13
157	Motility and Gi Function Studies Billing and Coding Guidelines: A Position Paper of The American Motility Society. American Journal of Gastroenterology, 2003, 98, 1228-1236.	0.2	12
158	Barrett's esophagus: endoscopic diagnosis. Annals of the New York Academy of Sciences, 2011, 1232, 53-75.	1.8	12
159	Clinical significance of recurrent gastroesophageal junction intestinal metaplasia after endoscopic eradication of Barrettâ€™s esophagus. Gastrointestinal Endoscopy, 2021, 93, 1250-1257.e3.	0.5	12
160	Editorial: Barrett's Esophagus and Adenocarcinoma. Journal of Clinical Gastroenterology, 1996, 23, 88-90.	1.1	12
161	Progression of Barretl's esophagus to high grade dysplasia and cancer: Preliminary results of the BEST (Barrett's esophagus study) trial. Gastroenterology, 2001, 120, A16-A17.	0.6	11
162	Eosinophilic pancreatitis presenting as a pancreatic mass with obstructive jaundice. Gastrointestinal Endoscopy, 2006, 63, 525-527.	0.5	11

#	Article	IF	Citations
163	Is Conventional Endoscopic Identification of Non-Erosive Reflux Disease Adequate?. Digestion, 2008, 78, 17-23.	1.2	11
164	Barrett's oesophagus: Frequency and prediction of dysplasia and cancer. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2015, 29, 125-138.	1.0	11
165	Barrett's oesophagus length is established at the time of initial endoscopy and does not change over time: results from a large multicentre cohort. Gut, 2015, 64, 1874-1880.	6.1	11
166	ATG7 Gene Expression as a Novel Tissue Biomarker in Eosinophilic Esophagitis. American Journal of Gastroenterology, 2016, 111, 151-153.	0.2	11
167	Highâ€resolution genomic alterations in Barrett's metaplasia of patients who progress to esophageal dysplasia and adenocarcinoma. International Journal of Cancer, 2019, 145, 2754-2766.	2.3	11
168	Low Risk of Progression of Barrettâ€™s Esophagus to Neoplasia in Women. Journal of Clinical Gastroenterology, 2021, 55, 321-326.	1.1	11
169	Predicting Barrett's Esophagus in Families: An Esophagus Translational Research Network (BETRNet) Model Fitting Clinical Data to a Familial Paradigm. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 727-735.	1.1	10
170	Immature myeloid progenitors promote disease progression in a mouse model of Barrett's-like metaplasia. Oncotarget, 2015, 6, 32980-33005.	0.8	10
171	Development and Validation of Web-Based Tool to Predict Lamina Propria Fibrosis in Eosinophilic Esophagitis. American Journal of Gastroenterology, 2022, 117, 272-279.	0.2	10
172	Barrett's Esophagus-Is It Bad for Your Health?. American Journal of Gastroenterology, 2005, 100, 2622-2623.	0.2	9
173	Proton pump inhibitor-responsive oesophageal eosinophilia: too early to change clinical practice. Gut, 2017, 66, 979-980.	6.1	9
174	Long-term outcomes for cryotherapy in Barrettâ€™s esophagus with high-grade dysplasia: just cracking the ice. Gastrointestinal Endoscopy, 2017, 86, 633-635.	0.5	9
175	Best Practices in Surveillance for Barrett's Esophagus. Gastrointestinal Endoscopy Clinics of North America, 2021, 31, 59-75.	0.6	9
176	Targeting the COX1/2-Driven thromboxane A2 pathway suppresses Barrett's esophagus and esophageal adenocarcinoma development. EBioMedicine, 2019, 49, 145-156.	2.7	8
177	Guideline to Practice: Diagnosis and Management of Barrett's Esophagus: An Updated ACG Guideline. American Journal of Gastroenterology, 2022, 117, 1177-1180.	0.2	8
178	Chemoprevention and Barrett's Esophagus: Decisions, Decisions. American Journal of Gastroenterology, 2008, 103, 2443-2445.	0.2	7
179	Radiofrequency Ablation of Barrett's Esophagus: Should Everybody Get it?. Gastroenterology, 2009, 136, 2399-2401.	0.6	7
180	Radiofrequency Ablation of Barrettâ€™s Esophagus: Letâ€™s Not Get Ahead of Ourselves. Digestive Diseases and Sciences, 2010, 55, 1811-1814.	1.1	7

#	Article	IF	Citations
181	Columnar islands in Barrett's esophagus: Do they impact Prague C&M criteria and dysplasia grade?. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1598-1603.	1.4	7
182	Modeling Esophagitis Using Human Three-Dimensional Organotypic Culture System. American Journal of Pathology, 2017, 187, 1787-1799.	1.9	7
183	Overestimation of the diagnosis of eosinophilic colitis with reliance on billing codes. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2434-2436.	2.0	7
184	Flow based single cell analysis of the immune landscape distinguishes Barrettâ€™s esophagus from adjacent normal tissue. Oncotarget, 2019, 10, 3592-3604.	0.8	7
185	Eosinophilic esophagitis: New insights into an emerging disease. Gastroenterology, 2006, 131, 2018-2020.	0.6	6
186	Evidence for DNA Damage Checkpoint Activation in Barrett Esophagus. Translational Oncology, 2010, 3, 33-42.	1.7	6
187	92 Durability of Epithelial Reversion After Radiofrequency Ablation: Follow-up of the AIM Dysplasia Trial. Gastroenterology, 2010, 138, S-16-S-17.	0.6	6
188	Management of Low-Grade Dysplasia in Barrettâ€™s Esophagus: Incremental Progress Continues. Gastroenterology, 2017, 152, 928-932.	0.6	6
189	Genomic regions associated with susceptibility to Barrettâ€™s esophagus and esophageal adenocarcinoma in African Americans: The cross BETRNet admixture study. PLoS ONE, 2017, 12, e0184962.	1.1	6
190	Type II achalasia is associated with a comparably favorable outcome following per oral endoscopic myotomy. Ecological Management and Restoration, 2021, 34, .	0.2	6
191	Rio de Janeiro Global Consensus on Landmarks, Definitions, and Classifications in Barrettâ€™s Esophagus: World Endoscopy Organization Delphi Study. Gastroenterology, 2022, 163, 84-96.e2.	0.6	6
192	Endoscopic surveillance of Barrett's esophagus. Techniques in Gastrointestinal Endoscopy, 2000, 2, 186-193.	0.3	5
193	Obesity and Gastroesophageal Reflux Disease: Another Piece of the Puzzle. Gastroenterology, 2008, 134, 1620-1622.	0.6	5
194	Barrett's Esophagus Surveillance: When, How Often, Does It Work?. Gastrointestinal Endoscopy Clinics of North America, 2011, 21, 9-24.	0.6	5
195	Barrett's Esophagus Translational Research Network (BETRNet): The Pivotal Role of Multi-institutional Collaboration in Esophageal Adenocarcinoma Research. Gastroenterology, 2014, 146, 1586-1590.	0.6	5
196	Control of Acid and Duodenogastroesophageal Reflux (DGER) in Patients With Barrettâ€™s Esophagus. American Journal of Gastroenterology, 2015, 110, 1143-1148.	0.2	5
197	Can FLIP guide therapy in idiopathic esophagogastric junction outflow obstruction?. Ecological Management and Restoration, 2022, 35, .	0.2	5
198	A Clinical Severity Index for Eosinophilic Esophagitis: Development, Consensus, and Future Directions. Journal of Allergy and Clinical Immunology, 2022, 150, 33-47.	1.5	5

#	Article	IF	Citations
199	Why is esophageal adenocarcinoma increasing in incidence?. Abdominal Imaging, 1998, 23, 539-542.	2.0	4
200	Pathogenesis of Gastroesophageal Reflux and Barrett Esophagus. Mayo Clinic Proceedings, 2001, 76, 226-234.	1.4	4
201	Turning an idea into a grant. Gastrointestinal Endoscopy, 2006, 64, S11-S13.	0.5	4
202	Laryngopharyngeal Reflux: Beauty is in The Eye of The Beholder. Gastroenterology, 2007, 133, 1379-1381.	0.6	4
203	Refractory GERD: Further Insights Into the Cause of Symptoms. Gastroenterology, 2008, 135, 1414-1415.	0.6	4
204	Inhibition of Transient Lower Esophageal Sphincter Relaxation in GERD: Will Lesogaberan Advance the Field?. Gastroenterology, 2010, 139, 377-379.	0.6	4
205	Probe-based confocal endomicroscopy in Barrett's esophagus: the real deal or another tease?. Gastrointestinal Endoscopy, 2011, 74, 473-476.	0.5	4
206	Barrett's esophagus: surveillance and reversal. Annals of the New York Academy of Sciences, 2011, 1232, 196-209.	1.8	4
207	Linkage and related analyses of Barrett's esophagus and its associated adenocarcinomas. Molecular Genetics & Genomic Medicine, 2016, 4, 407-419.	0.6	4
208	2017 David Sun Lecture: Screening and Surveillance of Barrettâ€™s Esophagus: Where Are We Now and What Does the Future Hold?. American Journal of Gastroenterology, 2019, 114, 64-70.	0.2	4
209	Is the age of diagnosis of esophageal adenocarcinoma getting younger? Analysis at a tertiary care center. Ecological Management and Restoration, 2020, 33, .	0.2	4
210	M1104 Predicting High-Grade Dysplasia (HGD) and Esophageal Adenocarcinoma (EAC) in Patients With Non-Dysplastic Barrett's Esophagus (BE): Results From a Large, Multicenter Cohort Study. Gastroenterology, 2010, 138, S-333.	0.6	3
211	Radiofrequency ablation for BarrettÊ¼s esophagus. Current Opinion in Gastroenterology, 2014, 30, 415-421.	1.0	3
212	Endoscopic submucosal dissection for Barrett-associated neoplasia: is it ready for the endoscopistâ€™s toolbox?. Endoscopy, 2015, 47, 97-98.	1.0	3
213	Age of diagnosis in familial Barrettâ€™s associated neoplasia. Familial Cancer, 2022, 21, 115-120.	0.9	3
214	Updated Guidelines for Diagnosing and Managing Barrett Esophagus. Gastroenterology and Hepatology, 2016, 12, 449-51.	0.2	3
215	How Exactly Do I Diagnose Intestinal Metaplasia in Barrettâ€™s Esophagus?. Gastroenterology, 2007, 133, 2060-2062.	0.6	2
216	Cutting to the chase: circumferential endoscopic mucosal resection for Barrett's neoplasia. Gut, 2010, 59, 1163-1164.	6.1	2

#	Article	IF	Citations
217	Eosinophilic Esophagitis. Gastroenterology Clinics of North America, 2014, 43, xiii.	1.0	2
218	An Unusual Cause of Abdominal Pain. Gastroenterology, 2015, 149, e1-e2.	0.6	2
219	Presentation of the Julius M. Friedenwald Medal to Anil K. Rustgi. Gastroenterology, 2017, 152, 2063-2067.	0.6	2
220	Low-grade dysplasia in Barrettâ€™s esophagus: More than meets the eye?. Gastrointestinal Endoscopy, 2021, 94, 909-911.	0.5	2
221	Gastroesophageal reflux disease. Current Opinion in Gastroenterology, 1999, 15, 333.	1.0	2
222	Current Management of Low-Grade Dysplasia in Barrett Esophagus. Gastroenterology and Hepatology, 2017, 13, 221-225.	0.2	2
223	887 Integrated Pathways of Fibrogenesis in Eosinophilic Esophagitis: Active Secretion of Th2 Cytokines and TGF-Î²1, and Binding of Activated Eosinophils Promote Collagen I and Fibronectin Production By Human Esophageal Mesenchymal Cells. Gastroenterology, 2009, 136, A-137.	0.6	1
224	Antireflux Therapy in Asthma: Is There Any Role?. Gastroenterology, 2009, 137, 1844-1846.	0.6	1
225	Su1461 The Impact of Wide-Area Endoluminal Resection on Endoscopic Therapy for Barrett's Dysplasia and Early Carcinoma. Gastrointestinal Endoscopy, 2013, 77, AB332.	0.5	1
226	Management of Earlyâ€stage Esophageal Neoplasia (MESEN) Consensus. World Journal of Surgery, 2014, 38, 96-105.	0.8	1
227	Barrettâ€™s Esophagus. Gastroenterology Clinics of North America, 2015, 44, xiii.	1.0	1
228	Gastroparesis. Gastroenterology Clinics of North America, 2015, 44, xiii.	1.0	1
229	Barrett's Esophagus. , 2019, , 279-290.e5.		1
230	Antroduodenal manometry. Digestive Diseases and Sciences, 1992, 37, 1927-1927.	1.1	0
231	Night Vision Goggles for Surveillance of Barrettâ€™s Esophagus: A Paradigm Shift is Coming!. Gastroenterology, 2007, 132, 1189-1191.	0.6	0
232	Cutting Endoscopically or Surgically for Superficial Esophageal Adenocarcinoma. Gastroenterology, 2007, 133, 360-362.	0.6	0
233	Diseases of the Esophagus. , 2012, , 874-886.		0
234	Update on Ablation for Barrettâ€™s Esophagus. Current Gastroenterology Reports, 2014, 16, 368.	1.1	0

#	Article	IF	Citations
235	Gastroesophageal Reflux Disease. Gastroenterology Clinics of North America, 2014, 43, xi-xii.	1.0	0
236	Upper GI Bleeding. Gastroenterology Clinics of North America, 2014, 43, xiii.	1.0	0
237	Biologics of IBD. Gastroenterology Clinics of North America, 2014, 43, xiii.	1.0	0
238	Hepatitis C Virus. Gastroenterology Clinics of North America, 2015, 44, xiii.	1.0	0
239	Four Approaches to Reinvigorate Learning for the 21st CenturyÂGastroenterologist. Gastroenterology, 2016, 151, 218-221.	0.6	0
240	Good news for the treatment of narrow-caliber esophagus in eosinophilic esophagitis. Gastrointestinal Endoscopy, 2020, 92, 54-55.	0.5	0
241	Editorial: fluticasone propionate orally disintegrating tabletsâ€"interesting concept but is it going anywhere? Authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2020, 51, 990-991.	1.9	0
242	Reply. Clinical Gastroenterology and Hepatology, 2021, , .	2.4	0
243	Transition of Care from Pediatric to Adult Care in Eosinophilic Esophagitis. Journal of Pediatric Gastroenterology and Nutrition, 2021, 73, 722-726.	0.9	0
244	Adenocarcinoma in Barrettâ€™s Esophagus: Signs, Symptoms and Endoscopic Appearance. , 2001, , 291-295.		0
245	Decision Making in Ablation: Disease, Patients, and Institutional Factors. , 2009, , 63-89.		0
246	In reply: Barium esophagography (February 2009). Cleveland Clinic Journal of Medicine, 2009, 76, 218.2-218.	0.6	0
247	Diagnosis and Surveillance of Barrett's Esophagus. , 2012, , 321-339.		0
248	Update on the use of radiofrequency ablation for treatment of barrett esophagus. Gastroenterology and Hepatology, 2013, 9, 447-9.	0.2	0
249	Novel Therapeutic Approaches to Eosinophilic Esophagitis. Gastroenterology and Hepatology, 2020, 16, 294-301.	0.2	0